Novartis AG Sponsored ADR (NVS)
Novartis to Buy Myricx Bio for Up to $1.5 Billion
The deal for the privately held U.K.-based biotechnology firm will help bolster Novartis's oncology capabilities.
Novartis to acquire UK-based Myricx Bio for up to $1.5 billion
Swiss drugmaker Novartis said on Monday it had agreed to pay up to $1.5 billion for U.K.-based biotechnology firm Myricx Bio in a deal expected to close in the second half of 2026.
NVS Gains EC Approval for SMA Therapy Itvisma in Broad Population
Novartis wins EC approval for Itvisma, the first gene replacement therapy for a broad SMA population, expanding treatment options from newborns to adults.
Novartis' Rhapsido Meets Primary Goal in Phase III Skin Disorder Study
Novartis reports phase III RemIND success for Rhapsido in chronic inducible urticaria, showing higher response rates and supporting new filings.
Novartis says rare muscle disease drug shows promise in early trial
Novartis said on Thursday an experimental drug, which it acquired as part of its $12 billion takeover of Avidity, showed promise in an early-to-mid-stage study in patients with a type of genetic muscle disorder characterized by slowly progressive muscle weakness.
Novartis Reports Positive Data for Neuromuscular Disorder Drug
NVS announces positive FORTITUDE data as del-brax met key endpoints, supporting its potential as a disease-modifying treatment for FSHD.
Implied Volatility Surging for Novartis Stock Options
Investors need to pay close attention to NVS stock based on the movements in the options market lately.
Novartis: Revenue Lags In Q1, Outlook Unchanged
Novartis missed Q1 revenue and EPS estimates, but key growth products remain strong, and full-year guidance was reaffirmed. Entresto U.S. sales eroded faster than I expected, but easier Y/Y comps and robust pipeline support a return to growth. NVS's key products Kisqali, Kesimpta, Leqvio, and Pluvicto continue to outperform, and Rhapsido is off to a strong start in the CSU market with additional clinical trial readouts on the way.
Novartis shares fall after weak Q1 hit by Entresto competition
Novartis reported first-quarter core operating profit and sales below market expectations, as generic competition for its top-selling heart drug Entresto weighed on results. Shares of the Swiss drugmaker declined about 3% in premarket trading on Tuesday following the earnings release.
Novartis CEO: We knew these first two quarters would be bumpy
Novartis CEO Vas Narasimhan discusses the company's first quarter earnings, which missed expectations amid increasing generic competition in the key U.S. market.
NVS SMA Drug Gets CHMP Backing, Malaria Drug Wins WHO Prequalification
Novartis secures CHMP backing for Itvisma in SMA and wins WHO nod for Coartem Baby, targeting critical gaps in rare disease and infant malaria care.
Novartis receives European Commission approval for Rhapsido skin disease drug
Novartis has received European Commission approval for its drug Rhapsido, an oral treatment for chronic spontaneous urticaria (CSU), the Swiss drugmaker said on Monday.
